摘要
目的:探讨不同疗程下干扰素结合抗病毒药物治疗1b型丙型病毒性肝炎的效果。方法:选取南京市高淳人民医院2017年6月-2019年11月收治的126例1b型丙型病毒性肝炎患者为研究对象按照随机数字表法将其分为三组,A组32例疗程24周,B组44例疗程48周,C组50例疗程72周,分别给予聚乙二醇(Peg-IFNα-2a)联合抗病毒药物利巴韦林,治疗结束后比较三组丙型肝炎病毒(hepatitis C virus,HCV)RNA水平变化及治疗效果。结果:A组患者4、12、24周及随访的RVR分别为59.38%、68.75%、87.50%、46.88%;B组患者4、12、24、48周及随访的RVR率值分别为75.00%、81.82%、84.09%、88.64%、70.45%,C组患者4、12、24、48、72周及随访的RVR率值分别为87.76%、89.80%、93.88%、95.92%、97.96%、95.92%,C组患者随访的RVR高于A组和B组(P<0.05)。三组持续病毒应答率(sustained virological response,SVR)分别为68.42%(13/19)、84.85%(28/33)、95.74%(45/47),三组比较差异有统计学意义(P<0.05)。三组患者均出现不同程度的不良反应,主要包括头痛、恶心、发热、疲倦、胸闷、脱发、头晕及白细胞减少。C组头痛、发热、疲倦、胸闷、脱发等症状发生率明显低于A组,且头痛、脱发发生率明显低于B组,差异有统计学意义(P<0.05)。结论:应用Peg-IFNα-2a联合抗病毒药物利巴韦林治疗1b型丙型病毒性肝炎,不同疗程具有不同的治疗效果,其中疗程为72周时具有很好的治疗效果,安全有效,值得在临床上推广应用。
Objective:To investigate the effect of interferon combined with antiviral drugs in the treatment of type 1b viral hepatitis C under different courses of treatment.Method:A total of 126 patients with type 1b hepatitis C who were admitted to Nanjing Gaochun People’s Hospital from June 2017 to November 2019 were selected as the research objects and divided into three groups according to the random number table method.The treatment course of 32 patients in group A was 24 weeks.Forty-four patients in group B were treated for 48 weeks,and 50 patients in group C were treated with polyethylene glycol (Peg-IFNα-2a) combined with antiviral drug Ribavirin for 72 weeks,hepatitis C virus) RNA level changes and treatment effects.Result:The rapid virological response rate (RVR) of group A at 4,12,and 24 weeks and follow-up were 59.38%,68.75%,87.50%,and 46.88%,respectively,and those of group B were 75.00%,81.82%,84.09%,88.64%,70.45%,and group C were 87.76%,89.80%,93.88%,95.92%,97.96%,and 95.92%,respectively.The follow-up RVR of group C was higher than that of group A and group B (P<0.05).The sustained virological response (SVR) rates of the three groups of HCV 1b patients were 68.42% (13/19),84.85% (28/33) and 95.74% (45/47),respectively,the difference was statistically significant (P<0.05).The three groups of patients had different degrees of adverse reactions,mainly including headache,nausea,fever,fatigue,chest tightness,hair loss,dizziness and leukopenia.The incidence of headache,fever,fatigue,chest tightness,hair loss and other symptoms in group C were significantly lower than those in group A,and the incidence of headache and hair loss were significantly lower than those in group B,and the differences were statistically significant (P<0.05).Conclusion:Application of Peg-IFNα-2a combined with antiviral drug Ribavirin in the treatment of type 1b viral hepatitis C.Different courses of treatment have different therapeutic effects.Among them,the treatment course of 72 weeks has a good therapeutic effect,which is safe and effective,and is worthy of clinical application.
作者
赵桂苹
贾佑雨
裴倩云
孔燕
ZHAO Guiping;JIA Youyu;PEI Qianyun;KONG Yan(不详;Nanjing Gaochun People’s Hospital,Nanjing 211300,China)
出处
《中外医学研究》
2022年第23期139-142,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
干扰素
抗病毒药物
丙型病毒性肝炎
不同疗程
Interferon
Antiviral drugs
Hepatitis C virus
Different treatment course
